Loading
A phase 2 trial of Pegfilgrastim in ovarian cancer, run by TORL Biotherapeutics, LLC, now recruiting.
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. is a phase 2 interventional study registered as NCT06690775 by TORL Biotherapeutics, LLC, with 230 participants planned, started 2024-11-20 and due to reach its primary completion in 2027-10. Interventions recorded: TORL-1-23, TORL-1-23, TORL-1-23, Pegfilgrastim (drug). Conditions listed: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TORL BioTherapeutics, Ovarian cancer.
Shares Pegfilgrastim, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Growth factors: G-CSF and febrile neutropenia prevention, Pegfilgrastim.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/